Search

Your search keyword '"Larenas-Linnemann D"' showing total 562 results

Search Constraints

Start Over You searched for: Author "Larenas-Linnemann D" Remove constraint Author: "Larenas-Linnemann D"
562 results on '"Larenas-Linnemann D"'

Search Results

1. Changes in Skin Test Aeroallergen Sensitization in Mexico Over the Past 14 Years and According to Climate

2. Adult Severe Asthma Registries: A Global and Growing Inventory

3. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

4. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

5. Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index

6. Perceptions and Management of Allergic Rhinitis Among Ecuadorian Otorhinolaryngologists: A Survey-Based Study

7. How does the efficacy and safety of Oralair® compare to other products on the market?

9. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

11. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

13. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

14. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

15. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

16. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

17. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

19. The ARIA-MeDALL hypothesis

20. Barriers of use of patient-reported outcome measures (PROMs) in asthma and rhinitis care: preliminary insights from the multinational ‘PROMUSE’ study

21. Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma

22. Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients

23. Physicians' preferences in the use of PROMs during asthma and allergic rhinitis clinical approach

24. Effectiveness of initiating biologics in severe asthma patients with high steroid exposure

27. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study

28. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

29. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

30. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

31. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.

32. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

33. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

34. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis

35. Work productivity in rhinitis using cell phones: The MASK pilot study

36. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

37. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

38. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

39. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

40. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

41. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

42. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

43. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

44. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

46. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

47. Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care

48. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper

49. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

50. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

Catalog

Books, media, physical & digital resources